Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025 ...Middle East

HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating...

Hence then, the article about significant os benefit with cadonilimab in first line advanced gastric cancer final analysis of compassion 15 presented at esmo 2025 was published today ( Sunday 19/10/2025 - 06:44 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025 )

Also on site :

• UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
• AI boom fuels fears of an industry bubble (VIDEO)
• Amazon Has 'Super Warm' and ‘Soft' Mini Sheepskin Boots on Sale for $50, and They're 'Worth Every Penny'